Somatostatin is a peptide with a potent and broad antisecretory action, which makes it an
invaluable drug target for the pharmacological management of pituitary adenomas and …

Prolactinomas account for approximately 40% of all pituitary adenomas and are an
important cause of hypogonadism and infertility. The ultimate goal of therapy for …

Somatostatin analogs (SA) are widely used in acromegaly, either as first-line or adjuvant
treatment after surgery. First-line treatment with these drugs is generally used in the patients …

Many different drugs affect thyroid function. Most of these drugs act at the level of the thyroid
in patients with normal thyroid function, or at the level of thyroid hormone absorption or …

Background There is a need for novel antitumor agents that demonstrate efficacy in currently
refractory tumors without adding to the toxicity of therapy. The somatostatin analogs, which …

Context: There is currently no medical therapy for Cushing's disease that targets the pituitary
adenoma. Availability of such a medical therapy would be a valuable therapeutic option for …

Mitogen-activated protein kinases (MAPKs) include ERK, p38, and JNK MAPK subfamilies,
which are crucial regulators of cellular physiology, cell pathology, and many diseases …

Objective: The clinically used somatostatin analogs, octreotide and lanreotide, act primarily
by binding to somatostatin receptor 2 (sst2). In contrast, the novel multireceptor ligand …

The most known effects of endogenous Cushing's syndrome are the phenotypic changes
and metabolic consequences. However, hypercortisolism can exert important effects on …

Background The response to first-generation somatostatin receptor ligands (SRLs) treatment
in acromegaly correlates with expression of somatostatin receptor subtype 2 (SSTR2) …